LOVENOX 30 MG / 0.3 ML
ENOXAPARIN SODIUM : 30 MG / 0.3 ML · DIN 02012472 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is LOVENOX?
LOVENOX 30 MG / 0.3 ML contains ENOXAPARIN SODIUM : 30 MG / 0.3 ML. It is listed in the Health Canada Drug Product Database under DIN 02012472, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 04-Feb-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LOVENOX used for?
LOVENOX (enoxaparin) is indicated for the prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing orthopedic surgery of the hip or knee, high risk abdominal, gynecological, or urological surgeries, and colorectal surgery. It is also indicated for the prophylaxis of deep vein thrombosis (DVT) in medical patients at moderate risk of DVT and who are bedridden due to moderate to severe acute cardiac insufficiency, acute respiratory failure, or acute respiratory infections. LOVENOX is also indicated for the prevention of thrombus formation in the extra-corporeal circulation during hemodialysis, the treatment of deep vein thrombosis with or without pulmonary embolism, the treatment of unstable angina or non-Q-wave myocardial infarction, and the treatment of acute ST-segment Elevation Myocardial Infarction (STEMI).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02012472 |
|---|---|
| Brand name | LOVENOX |
| Generic / active ingredient | ENOXAPARIN SODIUM : 30 MG / 0.3 ML |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 30 MG / 0.3 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B01AB05 ENOXAPARIN |
| AHFS class | 20:12.04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Feb-2012 |
| Original market date | 1993-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Single dose 30 mg/0.3 mL pre-filled syringes 27 G in packs of 10 syringes per carton, 2 pre-filled syringes with protective shield per blister, each in individual blister pack.Single dose 40 mg/0.4 mL pre-filled syringes 27 G in packs of 10 syringes per carton, 2 pre-filled syringes with protective shield per blister, each in individual blister pack.Single dose 60 mg/0.6 mL pre-filled syringes 27 G in packs of 10 syringes per carton, 2 pre-filled syringes with protective shield per blister, each in individual blister pack.Single dose 80 mg/0.8 mL pre-filled syringes 27 G in packs of 10 syringes per carton, 2 pre-filled syringes with protective shield per blister, each in individual blister pack.
What can be used instead?
Other Canadian products sharing ATC code B01AB05 ENOXAPARIN. 44 of 46 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AXBERI | 100 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540045 |
| AXBERI | 30 MG / 0.3 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02539977 |
| AXBERI | 40 MG / 0.4 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02539985 |
| AXBERI | 60 MG / 0.6 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540002 |
| AXBERI | 80 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540010 |
| AXBERI HP | 120 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540029 |
| AXBERI HP | 150 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540037 |
| ELONOX | 100 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532298 |
| ELONOX | 30 MG / 0.3 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532247 |
| ELONOX | 40 MG / 0.4 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532255 |
Who else supplies ENOXAPARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENOXAPARIN appears in 433 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.